Rep. Steve Cohen Sells Off Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Representative Steve Cohen (D-Tennessee) recently sold shares of Emergent BioSolutions Inc. (NYSE:EBS). In a filing disclosed on January 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Emergent BioSolutions stock on December 11th. The trade occurred in the Representative’s “STEPHENS SEP IRA” account.

Representative Steve Cohen also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Host Hotels & Resorts (NASDAQ:HST) on 12/11/2024.

Emergent BioSolutions Stock Performance

Shares of NYSE:EBS opened at $9.37 on Wednesday. The firm’s 50 day simple moving average is $9.36 and its 200-day simple moving average is $9.17. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions Inc. has a one year low of $1.42 and a one year high of $15.10. The firm has a market cap of $507.70 million, a PE ratio of -2.29 and a beta of 1.60.

Hedge Funds Weigh In On Emergent BioSolutions

A number of large investors have recently bought and sold shares of EBS. Acadian Asset Management LLC increased its holdings in shares of Emergent BioSolutions by 267.5% in the 2nd quarter. Acadian Asset Management LLC now owns 108,566 shares of the biopharmaceutical company’s stock valued at $739,000 after acquiring an additional 79,028 shares during the period. Headlands Technologies LLC bought a new stake in Emergent BioSolutions during the second quarter valued at about $969,000. American Century Companies Inc. grew its stake in Emergent BioSolutions by 240.9% in the second quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after purchasing an additional 623,201 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Emergent BioSolutions in the second quarter worth about $41,000. Finally, Federated Hermes Inc. lifted its position in shares of Emergent BioSolutions by 1,314.0% during the second quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after buying an additional 253,960 shares during the last quarter. Institutional investors own 78.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. StockNews.com upgraded Emergent BioSolutions from a “hold” rating to a “buy” rating in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Emergent BioSolutions in a research note on Friday, January 10th. Finally, Benchmark upped their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th.

About Representative Cohen

Steve Cohen (Democratic Party) is a member of the U.S. House, representing Tennessee’s 9th Congressional District. He assumed office on January 3, 2007. His current term ends on January 3, 2025. Cohen (Democratic Party) is running for re-election to the U.S. House to represent Tennessee’s 9th Congressional District. He declared candidacy for the Democratic primary scheduled on August 1, 2024. He represented District 30 of the Tennessee State Senate from 1983-2006. As a child, Cohen contracted polio. Cohen filed to run for his first elected office the same day that he first registered to vote. Cohen earned a bachelor’s degree from Vanderbilt and a J.D. from the University of Memphis School of Law. Prior to his election to the U.S. House, Cohen was a member of the Tennessee State Senate.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.